KRON RSI Chart
Last 7 days
-2.9%
Last 30 days
-16.0%
Last 90 days
-9.9%
Trailing 12 Months
-25.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 6.1M | 7.9M | 9.0M | 9.2M |
2022 | 330.0K | 871.0K | 2.1M | 3.9M |
2021 | 635.0K | 502.0K | 372.0K | 320.0K |
2020 | 751.0K | 800.0K | 849.0K | 898.0K |
2019 | 0 | 0 | 0 | 702.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 21, 2024 | lin charles y | sold | -12,684 | 1.0539 | -12,036 | sr vp, research & development |
Feb 21, 2024 | frisbee allison | sold | -12,757 | 1.0539 | -12,105 | sr vp, corp operations & legal |
Feb 21, 2024 | olek elizabeth a | sold | -7,765 | 1.0539 | -7,368 | sr vp, clinical science |
Feb 15, 2024 | bischofberger norbert w | acquired | - | - | 270,339 | president & ceo |
Jan 04, 2024 | dinsmore christopher | sold | -8,718 | 1.1836 | -7,366 | chief scientific officer |
Jan 04, 2024 | dimartino jorge | sold | -14,213 | 1.1836 | -12,009 | chief medical officer & vp |
Jan 04, 2024 | kosacz barbara | sold | -12,636 | 1.1836 | -10,676 | coo & general counsel |
Dec 12, 2023 | dimartino jorge | sold | -22,663 | 1.305 | -17,367 | chief medical officer & vp |
Dec 12, 2023 | dinsmore christopher | sold | -13,091 | 1.305 | -10,032 | chief scientific officer |
Nov 17, 2023 | bischofberger norbert w | bought | 106,162 | 1.084 | 97,935 | president & ceo |
Which funds bought or sold KRON recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 12, 2024 | Vida Ventures Advisors, LLC | unchanged | - | 138,265 | 3,594,910 | 2.00% |
Apr 11, 2024 | Dakota Community Bank & Trust NA | unchanged | - | 47.00 | 1,226 | 0.01% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 0.73 | -69,028 | 2,125,850 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 43.32 | 13,472 | 49,108 | -% |
Feb 26, 2024 | PERCEPTIVE ADVISORS LLC | unchanged | - | -87,637 | 2,190,930 | 0.05% |
Feb 16, 2024 | BLUEFIN CAPITAL MANAGEMENT, LLC | new | - | 31,124 | 31,124 | -% |
Feb 16, 2024 | GSA CAPITAL PARTNERS LLP | reduced | -53.88 | -40,000 | 31,000 | -% |
Feb 15, 2024 | JANE STREET GROUP, LLC | reduced | -40.01 | -17,499 | 23,849 | -% |
Feb 15, 2024 | Coastal Bridge Advisors, LLC | unchanged | - | -2,598 | 64,960 | 0.02% |
Feb 15, 2024 | BARCLAYS PLC | unchanged | - | -1,000 | 20,000 | -% |
Unveiling Kronos Bio Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Kronos Bio Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 40.6B | 6.8B | -8.61 | 5.92 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.1B | 1.8B | -41.1 | 9.9 | ||||
BMRN | 15.5B | 2.4B | 92.47 | 6.41 | ||||
INCY | 11.5B | 3.7B | 19.23 | 3.11 | ||||
MID-CAP | ||||||||
APLS | 5.8B | 396.6M | -10.93 | 14.57 | ||||
BBIO | 4.3B | - | -6.55 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.16 | 12.52 | ||||
ARWR | 2.7B | 240.7M | -9.13 | 12.18 | ||||
ACAD | 2.7B | 726.4M | -43.85 | 3.7 | ||||
SMALL-CAP | ||||||||
CPRX | 1.7B | 398.2M | 24.23 | 4.35 | ||||
NVAX | 552.8M | 983.7M | -1.01 | 0.56 | ||||
CRBP | 351.2M | 881.7K | -7.87 | 466.16 | ||||
INO | 236.5M | 4.9M | -1.75 | 48.6 | ||||
IBIO | 5.9M | 2.1M | -0.22 | 2.14 |
Kronos Bio Inc News
Income Statement (Quarterly) | |||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 |
Revenue | -17.4% | 2,024 | 2,451 | 2,427 | 2,255 | 1,900 | 1,282 | 627 | 102 | 72.00 | 70.00 | 86.00 | 92.00 | 124 | 200 | 219 | 355 | 333 | 311 |
Operating Expenses | -14.7% | 29,630 | 34,742 | 34,032 | 29,714 | 33,682 | 33,538 | 33,530 | 36,365 | 62,406 | 33,673 | 29,141 | 26,178 | 21,088 | 20,809 | 8,798 | 7,349 | - | 4,323 |
S&GA Expenses | 16.3% | 10,926 | 9,398 | 11,359 | 10,056 | 10,514 | 10,135 | 10,824 | 11,927 | 11,587 | 8,985 | 9,339 | 8,584 | 7,963 | 4,054 | 1,623 | 1,154 | - | 797 |
R&D Expenses | -26.2% | 18,704 | 25,344 | 22,673 | 19,658 | 23,168 | 23,403 | 22,706 | 24,438 | 50,819 | 24,688 | 19,802 | 17,594 | 13,125 | 16,755 | 7,175 | 6,195 | - | 3,526 |
Interest Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3,889 | - | 1.00 | - | 1.00 |
Net Income | 19.3% | -25,320 | -31,374 | -29,741 | -26,238 | -31,782 | -32,256 | -32,903 | -36,263 | -62,334 | -33,603 | -29,055 | -26,086 | -88,444 | -39,713 | -8,579 | -6,995 | -16,117 | -4,013 |
Net Income Margin | 6.7% | -12.30* | -13.19* | -15.26* | -20.31* | -34.06* | -54.35* | -78.04* | -132.42* | -472.12* | -352.96* | -365.14* | -256.41* | -160.06* | - | - | - | - | - |
Free Cashflow | -9.9% | -25,055 | -22,800 | -25,333 | -6,073 | -22,580 | -22,467 | -22,606 | -23,850 | -59,000 | -21,066 | -21,615 | -20,503 | -19,312 | - | - | - | - | - |
Balance Sheet | ||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
Assets | -10.4% | 213 | 238 | 261 | 289 | 295 | 318 | 341 | 366 | 391 | 448 | 472 | 488 | 512 | 263 | 103 |
Current Assets | -6.7% | 179 | 192 | 224 | 232 | 244 | 265 | 275 | 311 | 348 | 403 | 424 | 405 | 420 | 213 | 93.00 |
Cash Equivalents | 11.7% | 64.00 | 58.00 | 44.00 | 62.00 | 76.00 | 67.00 | 86.00 | 149 | 200 | 217 | 186 | 141 | 250 | 156 | 33.00 |
Net PPE | -9.4% | 10.00 | 11.00 | 12.00 | 13.00 | 13.00 | - | - | - | 15.00 | - | - | - | - | - | - |
Liabilities | -8.7% | 54.00 | 59.00 | 57.00 | 63.00 | 50.00 | 50.00 | 49.00 | 49.00 | 46.00 | 49.00 | 48.00 | 43.00 | 46.00 | 216 | - |
Current Liabilities | -3.8% | 25.00 | 26.00 | 22.00 | 25.00 | 21.00 | 20.00 | 18.00 | 17.00 | 14.00 | 15.00 | 13.00 | 11.00 | 13.00 | 184 | 3.00 |
Shareholder's Equity | -10.9% | 159 | 179 | 203 | 226 | 244 | 268 | 292 | 317 | 345 | 399 | 424 | 445 | 466 | - | - |
Retained Earnings | -5.2% | -508 | -483 | -452 | -422 | -396 | -364 | -332 | -299 | -262 | -200 | -167 | -137 | -111 | -78.75 | -23.46 |
Additional Paid-In Capital | 0.8% | 668 | 662 | 656 | 648 | 641 | 633 | 625 | 616 | 608 | 600 | 591 | 583 | 577 | 2.00 | 0.00 |
Shares Outstanding | 1.3% | 59.00 | 58.00 | 58.00 | 57.00 | 57.00 | 56.00 | 56.00 | 56.00 | 56.00 | 55.00 | 54.00 | 54.00 | - | - | - |
Float | - | - | - | 48.00 | - | - | - | 205 | - | - | - | 1,300 | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2018Q4 |
Cashflow From Operations | -10.8% | -25,024 | -22,586 | -25,025 | -5,947 | -22,528 | -22,394 | -22,520 | -23,484 | -58,522 | -20,140 | -20,264 | -18,998 | -15,630 | -10,286 | -4,930 | -7,066 | - | - | - |
Share Based Compensation | -17.8% | 5,173 | 6,296 | 6,906 | 6,607 | 7,689 | 7,461 | 8,207 | 7,788 | 7,404 | 7,137 | 6,432 | 5,238 | 2,019 | 1,253 | 293 | 188 | - | 23.00 | - |
Cashflow From Investing | -11.8% | 31,560 | 35,789 | 5,374 | -6,355 | 31,736 | 3,107 | -40,729 | -26,336 | 38,749 | 50,094 | 63,030 | -88,149 | -158,755 | -20,781 | 13,991 | 5,310 | - | - | - |
Cashflow From Financing | - | 191 | - | 376 | - | -716 | 628 | 410 | 529 | 1,050 | 1,381 | 1,444 | 585 | 266,199 | 149,297 | 105 | 12.00 | - | - | - |
Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Statement [Abstract] | ||
Revenue | $ 6,288 | $ 0 |
Operating expenses: | ||
Research and development | 86,379 | 93,715 |
General and administrative | 41,739 | 43,400 |
Total operating expenses | 128,118 | 137,115 |
Loss from operations | (121,830) | (137,115) |
Other income (expense), net: | ||
Interest income and other expense, net | 9,157 | 3,911 |
Total other income (expense), net | 9,157 | 3,911 |
Net loss | (112,673) | (133,204) |
Other comprehensive income (loss): | ||
Net unrealized gain (loss) on available-for-sale securities | 811 | (753) |
Net comprehensive loss | $ (111,862) | $ (133,957) |
Net loss per share, basic (in dollars per share) | $ (1.95) | $ (2.37) |
Net loss per share, diluted (in dollars per share) | $ (1.95) | $ (2.37) |
Weighted-average number of shares used to compute net loss per share, basic (in shares) | 57,744 | 56,201 |
Weighted-average number of shares used to compute net loss per share, diluted (in shares) | 57,744 | 56,201 |
Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 64,326 | $ 75,973 |
Short-term investments | 108,671 | 162,212 |
Prepaid expenses and other current assets | 5,781 | 6,106 |
Total current assets | 178,778 | 244,291 |
Long-term investments | 1,989 | 9,762 |
Property and equipment, net | 10,252 | 12,985 |
Operating lease right-of-use assets | 19,657 | 24,707 |
Restricted cash | 2,026 | 2,026 |
Other noncurrent assets | 577 | 1,167 |
Total assets | 213,279 | 294,938 |
Current liabilities | ||
Accounts payable | 883 | 5,047 |
Accrued expenses | 10,931 | 12,963 |
Current portion of operating lease liabilities | 2,893 | 2,347 |
Current portion of deferred revenue | 9,584 | 0 |
Current portion of other liabilities | 404 | 1,129 |
Total current liabilities | 24,695 | 21,486 |
Noncurrent operating lease liabilities | 25,379 | 28,744 |
Deferred revenue, net of current portion | 4,127 | 0 |
Other noncurrent liabilities | 0 | 209 |
Total liabilities | 54,201 | 50,439 |
Commitments and contingencies (Note 8) | ||
Stockholder's equity | ||
Preferred stock, $0.001 par value; 10,000 authorized; no shares issued and outstanding | ||
Common stock, $0.001 par value, 200,000 shares authorized as of December 31, 2023 and December 31, 2022; 58,946 and 56,967 shares issued and outstanding as of December 31, 2023 and 2022, respectively. | 59 | 57 |
Additional paid-in capital | 667,861 | 641,422 |
Accumulated deficit | (508,861) | (396,188) |
Accumulated other comprehensive income (loss) | 19 | (792) |
Total stockholders' equity | 159,078 | 244,499 |
Total liabilities and stockholders’ equity | $ 213,279 | $ 294,938 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |